Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

82.00EUR
30 Jan 2015
Change (% chg)

€-0.26 (-0.32%)
Prev Close
€82.26
Open
€82.94
Day's High
€83.03
Day's Low
€81.37
Volume
3,876,370
Avg. Vol
3,455,794
52-wk High
€89.95
52-wk Low
€68.29

SASY.PA

Chart for SASY.PA

About

Sanofi, formerly Sanofi-Aventis is a global and diversified healthcare company. The Company discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi focuses on the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer... (more)

Overall

Beta: 0.61
Market Cap(Mil.): €108,812.00
Shares Outstanding(Mil.): 1,326.97
Dividend: 2.80
Yield (%): 3.41

Financials

  SASY.PA Industry Sector
P/E (TTM): 26.57 37.76 38.54
EPS (TTM): 3.09 -- --
ROI: -- 18.79 18.06
ROE: -- 19.44 18.83
Search Stocks

Three months on, fruitless CEO search overshadows Sanofi

PARIS - Barring a last-minute breakthrough, drugs firm Sanofi's Chairman Serge Weinberg may have to acknowledge in his results presentation next week that the hunt for a new chief executive is not going well.

30 Jan 2015

Three months on, fruitless CEO search overshadows Sanofi

PARIS, Jan 30 - Barring a last-minute breakthrough, drugs firm Sanofi's Chairman Serge Weinberg may have to acknowledge in his results presentation next week that the hunt for a new chief executive is not going well.

30 Jan 2015

Regeneron/Sanofi cholesterol drug gets FDA priority review

- Regeneron Pharmaceuticals on Monday said U.S. health regulators accepted its application to review a potent cholesterol drug on a priority basis, potentially giving it the upper hand in a fierce race with Amgen to bring a new medicine from the promising class to market.

26 Jan 2015

Regeneron/Sanofi cholesterol drug gets FDA priority review

Jan 26 - Regeneron Pharmaceuticals on Monday said U.S. health regulators accepted its application to review a potent cholesterol drug on a priority basis, potentially giving it the upper hand in a fierce race with Amgen to bring a new medicine from the promising class to market.

26 Jan 2015

Ousted Sanofi CEO gets 4.44 million euro severance package

PARIS - European pharmaceuticals group Sanofi on Thursday said it had agreed to pay 4.44 million euros ($5.06 million) in total to ousted chief executive Chris Viehbacher.

22 Jan 2015

UPDATE 1-Ousted Sanofi CEO gets 4.44 mln eur severance package

PARIS, Jan 22 - European pharmaceuticals group Sanofi on Thursday said it had agreed to pay 4.44 million euros ($5.06 million) in total to ousted chief executive Chris Viehbacher.

22 Jan 2015

Sanofi grants ousted CEO Viehbacher 2.96 mln eur severance payment

PARIS, Jan 22 - European pharmaceuticals group Sanofi said former chief executive Christopher Viehbacher would receive 2.96 million euros ($3.37 million) as a severance payment following his ouster last autumn.

22 Jan 2015

Takeda's Weber was approached for Sanofi CEO job but not interested

DAVOS - Christophe Weber, chief operating officer of Takeda Pharmaceutical Co., said on Wednesday he had been approached in connection with the vacant chief executive post at French drugs group Sanofi but decided to stay put.

21 Jan 2015

Takeda's Weber was approached for Sanofi CEO job but not interested

DAVOS, Jan 21 - Christophe Weber, chief operating officer of Takeda Pharmaceutical Co., said on Wednesday he had been approached in connection with the vacant chief executive post at French drugs group Sanofi but decided to stay put.

21 Jan 2015

BRIEF-Sanofi receives EU approval for dog parasite treatment

* Says the European Commission has approved NexGard Spectra beef-flavored chews for dogs for the treatment of flea and tick infestations, the prevention of heartworm disease and/or the treatment of intestinal worms Further company coverage:

19 Jan 2015

Earnings vs. Estimates

Search Stocks